Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Fácila L, Salgado-Barreira Á, Reyes-Santías F, Romero-Menor C, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Sandin M, Pamias RF, Bañeras J, García PB, Lorenzo MC, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Seijas-Amigo J, et al. Among authors: valle a. J Cardiovasc Pharmacol. 2023 Jan 1;81(1):70-75. doi: 10.1097/FJC.0000000000001365. J Cardiovasc Pharmacol. 2023. PMID: 36219195
Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials.
Cordero A, Nuñez J, Bertomeu-González V, Fácila L, Quintanilla MA, Rodríguez-Mañero M, Escribano D, Valle A, de la Espriella R, Torres-Llergo J, Bayés-Genís A, González-Juanatey JR. Cordero A, et al. Among authors: valle a. Am J Ther. 2022 Sep-Oct 01;29(5):e572-e575. doi: 10.1097/MJT.0000000000001503. Am J Ther. 2022. PMID: 36074989 No abstract available.
Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes.
de la Espriella R, Bayés-Genís A, Morillas H, Bravo R, Vidal V, Núñez E, Santas E, Miñana G, Sanchis J, Fácila L, Torres F, Górriz JL, Valle A, Núñez J. de la Espriella R, et al. Among authors: valle a. ESC Heart Fail. 2020 Dec;7(6):3792-3800. doi: 10.1002/ehf2.12965. Epub 2020 Sep 22. ESC Heart Fail. 2020. PMID: 32964683 Free PMC article.
Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction-a substudy of the DAPA-VO2 study.
Mora-Fernández C, Pérez A, Mollar A, Palau P, Amiguet M, de la Espriella R, Sanchis J, Górriz JL, Soler MJ, Navarro-González JF, Núñez J; DAPA-VO2 Investigators; DAPA-VO Investigators. Mora-Fernández C, et al. Front Cardiovasc Med. 2023 Aug 25;10:1242108. doi: 10.3389/fcvm.2023.1242108. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37745119 Free PMC article.
Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee. SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee. Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):458-465. doi: 10.1016/j.rec.2021.11.023. Epub 2022 Feb 18. Rev Esp Cardiol (Engl Ed). 2022. PMID: 35190290 English, Spanish. No abstract available.
Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure.
de la Espriella R, Amiguet M, Miñana G, Rodríguez JC, Moyano P, Segarra D, Fernández J, Santas E, Núñez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodí V, Górriz JL, Navarro J, Codina P, Voors AA, Bayés-Genís A, Núñez J. de la Espriella R, et al. Among authors: valle a. Eur J Heart Fail. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. Epub 2022 Aug 29. Eur J Heart Fail. 2022. PMID: 36054502 Free article.
Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure.
Núñez J, Bayés-Genís A, Revuelta-López E, Miñana G, Santas E, Ter Maaten JM, de la Espriella R, Carratalá A, Lorenzo M, Palau P, Llàcer P, Valle A, Bodi V, Núñez E, Lupón J, Lang C, Ng LL, Metra M, Sanchis J, Voors AA. Núñez J, et al. Among authors: valle a. Rev Esp Cardiol (Engl Ed). 2022 Apr;75(4):316-324. doi: 10.1016/j.rec.2021.02.002. Epub 2021 Mar 19. Rev Esp Cardiol (Engl Ed). 2022. PMID: 33745912 English, Spanish.
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.
Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, Santas E, Miñana G, Bodí V, Sanchis J, Valle A, Chorro FJ, Llácer P, Bayés-Genís A, Núñez J. Palau P, et al. Among authors: valle a. J Am Coll Cardiol. 2021 Nov 23;78(21):2042-2056. doi: 10.1016/j.jacc.2021.08.073. J Am Coll Cardiol. 2021. PMID: 34794685 Free article. Clinical Trial.
Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2 ): a randomized clinical trial.
Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ, de la Espriella R, Miñana G, Mezcua AR, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Górriz JL, Baýes-Genís A, Núñez J; DAPA-VO2 Investigators (see Appendix). Palau P, et al. Among authors: valle a. Eur J Heart Fail. 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. Epub 2022 Jun 6. Eur J Heart Fail. 2022. PMID: 35604416 Free article. Clinical Trial.
1,001 results